← Russell 3000 cross-section

INCY INCYTE CORP

Trailing twelve months to 2026-03-31 · as filed 2026-04-28, not restated
Healthcare

Scale

Market cap
$25.9bn
Revenue TTM
$5.4bn
Net income TTM
$1.4bn
Free cash flow
Composite score
77.8
Sector rank
#377

Valuation

P / E
18.1
EV / EBITDA
13.2
EV / sales
4.2
FCF yield
Earnings yield vs 10-yr
0.79pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
26.7%
EBITDA margin
31.8%
ROE
25.5%
ROIC
74.5%
Revenue growth
21.5%

Insider activity, last 90 days

Net open-market
$-15.67m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Results of Operations We recorded net income of $585.6 million and basic net income per share of $2.92 and diluted net income per share of $2.81 for the three months ended June 30, 2026, as compared to net income of $405.0 million and basic net income per share of $2.09 and diluted net income per share of $2.04 in the corresponding period in 2025. We recorded net income of $888.9 million and basic net income per share of $4.45 and diluted net income per share of $4.28 for the six months ended June 30, 2026, as compared to net income of $563.2 million and basic net income per share of $2.91 and diluted net income per share of $2.84 in the corresponding period in 2025. …INCYTE CORP, 10-Q, period ended 2026-06-30, filed 2026-07-28

Read the full passage →